Application of ribavirin in preparation of medicine for preventing and treating learning and memory disorders

Abstract

The invention discloses an application of ribavirin in preparation of a medicine for preventing and treating learning and memory disorders. According to the method, the influence of ribavirin on the aspect of improving learning memory is evaluated by utilizing a caenorhabditis elegans model. Pharmacodynamic experiment results show that ribavirin can obviously improve the aversion chemical tropism of caenorhabditis elegans on the third day, the sixth day and the ninth day, and it is prompted that ribavirin can be used for preparing the medicine for preventing and treating learning and memory impairment. According to the invention, the indication range of ribavirin is widened, and the ribavirin has important clinical significance.

Description

Technical Field

[0001] The invention belongs to the field of drug application, and specifically relates to the application of ribavirin in preparing drugs for preventing and treating learning and memory disorders. Background Art

[0002] Learning and memory disorders are major research and treatment problems in neuroscience and clinical medicine. Their etiology is complex, involving multiple mechanisms such as neuroinflammation, oxidative stress, neurotransmitter imbalance, and impaired synaptic plasticity of neural networks. Current treatments such as acetylcholinesterase inhibitors and NMDA receptor antagonists show certain efficacy in some cases, but there are still problems such as limited efficacy and significant side effects. Therefore, it is particularly important to explore new drugs and treatments to improve learning and memory functions.

[0003] Ribavirin is a broad-spectrum antiviral drug. Recent studies have shown that it has potential effects in neuroprotection and cognitive function improvement. However, there has been no systematic research and invention on its specific application and mechanism in learning and memory disorders. The present invention proposes a learning and memory enhancement method based on ribavirin, which provides a new drug intervention approach for the treatment of learning and memory disorders. Summary of the invention

[0004] In view of this, the object of the present invention is to provide the use of ribavirin in the preparation of a drug for preventing and treating learning and memory disorders.

[0005] In order to solve the above technical problems, the present invention provides the following technical solutions: The present invention firstly provides the application of ribavirin in preparing medicine for preventing and treating learning and memory disorders.

[0006] The learning and memory impairment described in the present invention refers to age-related learning and memory impairment.

[0007] Furthermore, the age-related learning and memory disorders include short-term memory disorders and long-term memory disorders.

[0008] Furthermore, the age-related learning and memory disorders include learning and memory disorders caused by neuronal aging, learning and memory disorders caused by atrophy of memory-related brain areas, and learning and memory disorders caused by changes in neurotransmitters in the brain.

[0009] The present invention also provides a pharmaceutical composition, comprising ribavirin as one of the main active ingredients.

[0010] The present invention also provides a pharmaceutical preparation, comprising ribavirin and a pharmaceutically acceptable carrier.

[0011] The pharmaceutical preparations include, but are not limited to, injections, oral preparations, topical preparations, and the like.

[0012] The administration methods of the pharmaceutical preparation include, but are not limited to, oral administration, intravenous injection, subcutaneous injection, intramuscular injection, intrathecal injection, inhalation administration, etc.

[0013] The chemotaxis of ribavirin on learning and memory was studied using the Caenorhabditis elegans model. The results showed that ribavirin can significantly improve the chemical chemotaxis of Caenorhabditis elegans, suggesting that it can be used to prepare drugs for the prevention and treatment of learning and memory disorders.

[0014] The invention provides a new application of ribavirin in preventing and treating learning and memory disorders, and broadens the new indications of the drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is the chemotaxis of learning and memory on the third day after 3 days of drug administration and no drug administration.

[0016] Figure 2 This is the chemotaxis of learning and memory on the sixth day after 3 days of drug administration and no drug administration.

[0017] Figure 3 This is the chemotaxis of learning and memory on the ninth day after 3 days of drug administration and no drug administration. DETAILED DESCRIPTION

[0018] The present invention is described in detail below in conjunction with the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0019] In the present invention, according to previous studies (Ribavirin extends the lifespan of Caenorhabditis elegans through AMPK-TOR Signaling), ribavirin is safe at a concentration of 10 μg / ml and also has the effect of prolonging lifespan, and this dose is used as the administration concentration for Caenorhabditis elegans. Example

[0020] Use lysis solution (3% NaClO solution, 1mol / L NaOH solution and water) to lyse the ovipositing stage Caenorhabditis elegans to obtain enough eggs. After culturing for 18 to 22 hours, collect the nematodes that have hatched to the L1 stage with K solution (0.3g NaCl, 1g KCl and 500mL water), centrifuge and discard the supernatant, add K solution, and inoculate into NGM medium for culture. The L1 stage Caenorhabditis elegans was inoculated into NGM solid medium containing ribavirin and cultured for 3 days to determine the learning and memory effect of Caenorhabditis elegans. The NGM solid medium includes 3g sodium chloride, 1.5g tryptone, 18g agar, 1mL 1M magnesium sulfate, 1mL 1M calcium chloride, 25mL 1M potassium phosphate buffer, 1mL 3mg / L cholesterol and 1L water.

[0021] L4 stage Caenorhabditis elegans was inoculated into NGM solid culture medium containing ribavirin and cultured for 3 days. The effect of ribavirin on improving learning and memory of Caenorhabditis elegans was evaluated based on the aversive chemical tropism of Caenorhabditis elegans on the third, sixth and ninth days.

[0022] Evaluation of the chemical tropism of Caenorhabditis elegans Method for evaluating the learning and memory ability of nematodes: Use a cork borer to cut an agar block from an NGM medium containing 100 mM NaCl, set two points on an NGM medium without NaCl, one point as a control, and the other point with a 100 mM NaCl agar block. Then leave this assay plate overnight (14-24 hours). During the test, adult D3, D6, and D9 nematodes (about 600 nematodes, three repeated experiments) that were drug-treated for 72 hours and blank control at the L4 stage of the nematodes were placed on the NGM medium and starved for 4 hours, then placed in the center of the test medium, and a drop of NaN3 was added to the two points set, left for 30 minutes, observed and recorded. Index = (nematodes placed on the NaCl agar block - nematodes at the control point) / total number of nematodes on the medium.

[0023] Results Figure 1-3 ,from Figure 1 It can be seen that the chemotaxis of the non-drug group on the third day of learning and memory of Caenorhabditis elegans was between 0.05 and 0.1, and the chemotaxis of the drug-treated group was between 0.15 and 0.2. The index of the Ribavirin group was significantly higher than that of the Control group, indicating that Ribavirin has a significant improving effect on this indicator.

[0024] from Figure 2 It can be seen that the chemotaxis of the non-drug group on the sixth day of learning and memory of Caenorhabditis elegans was between 0.05 and 0.1, and the chemotaxis of the drug-treated group was between 0.15 and 0.2. The index of the Ribavirin group was significantly higher than that of the Control group, indicating that Ribavirin had a significant improving effect on this indicator.

[0025] from Figure 3 It can be seen that the chemotaxis of the non-drug group on the ninth day of learning and memory of Caenorhabditis elegans was between 0.05 and 0.1, and the chemotaxis of the drug-treated group was between 0.1 and 0.15. The index of the Ribavirin group was significantly higher than that of the Control group, indicating that Ribavirin had a significant improving effect on this indicator.

[0026] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. The use of ribavirin in the preparation of drugs for preventing and treating learning and memory disorders.

2. The use according to claim 1, characterized in that: The learning and memory disorder refers to age-related learning and memory disorder.

3. The use according to claim 2, characterized in that: The age-related learning and memory impairment includes short-term memory impairment and long-term memory impairment.

4. The use according to claim 2, characterized in that: The age-related learning and memory disorders include learning and memory disorders caused by neuronal aging, learning and memory disorders caused by atrophy of brain areas related to memory, and learning and memory disorders caused by changes in neurotransmitters in the brain.

5. A pharmaceutical preparation for preventing and treating learning and memory disorders, characterized in that: Includes ribavirin as one of the main active ingredients.

6. The pharmaceutical preparation for preventing and treating learning and memory disorders according to claim 5, characterized in that: Also included are pharmaceutically acceptable carriers.

7. The pharmaceutical preparation for preventing and treating learning and memory disorders according to claim 6, characterized in that: The pharmaceutical preparations include injections, oral preparations, and topical preparations.

8. The pharmaceutical preparation for preventing and treating learning and memory disorders according to claim 7, characterized in that: The administration methods of the pharmaceutical preparation include oral administration, intravenous injection, subcutaneous injection, intramuscular injection, intrathecal injection and inhalation administration.

Images